1. Home >
  2. Safety >
  3. Adverse Reactions

Adverse reactions

The proportion of subjects who discontinued treatment at Week 96 due to ARs of any severity was 1.5% with VEMLIDY and 0.9% with TDF. At Week 144, the discontinuation rates due to ARs of any severity were 1.6% with VEMLIDY and 1.6% with TDF.1,2

Adverse reactionsa (all grades) reported in ≥5% of subjects on VEMLIDY in Trials 108 and 110 (Week 96 and Week 144 analyses)

Table depicting adverse reactions at Week 96 and Week 144 for VEMLIDY® (tenofovir alafenamide)

Differences were observed between VEMLIDY and TDF in certain lipid parameters1,2

In Trials 108 and 110:

  • Week 96: Mean changes from baseline in low-density lipoprotein cholesterol (LDL-C; fasted) and triglycerides (TG; fasted) were +7 mg/dL and +13 mg/dL for VEMLIDY, versus -10 mg/dL and -7 mg/dL for TDF1
  • Week 144: Mean changes from baseline in LDL-C (fasted) and TG (fasted) were +8 mg/dL and +18 mg/dL for VEMLIDY, versus -8 mg/dL and -2 mg/dL for TDF2
  • Week 240: Mean changes from baseline in LDL-C (fasted) and TG (fasted) were +23 mg/dL and +18 mg/dL for VEMLIDY 5-year patients, +22 mg/dL and +36 mg/dL for patients who switched from TDF to VEMLIDY at Week 96, and +19 mg/dL and +24 mg/dL for patients who switched from TDF to VEMLIDY at Week 1442

In Trial 4018:

  • Week 48: Changes from baseline in lipid parameters in the VEMLIDY and TDF groups were similar to those observed in Trials 108 and 110 at Week 961
  • Week 96: Lipid parameters in patients who were switched from TDF to VEMLIDY at Week 48 were similar to those of patients who continued on VEMLIDY2

5-year safety data1,2

Pooled Safety Analysis (Week 240): Pooled safety analysis (observed data) from Trials 108 and 110 was assessed at Week 240. This analysis includes 866 subjects who initiated VEMLIDY at baseline, 180 subjects who switched from TDF to TAF at Week 96, and 202 subjects who switched from TDF to TAF at week 144.

Most common ARs (all grades) reported in ≥2% of subjects on VEMLIDY who entered the open-label extension (Week 240 analysis)

Table depicting adverse reactions at Week 240 for VEMLIDY® (tenofovir alafenamide)

The 5-year data is not presented in the VEMLIDY label.

HCC surveillance in Trials 108 and 110 through Week 96

At Week 240, there were a total of 19 cases (1.5% incidence) of hepatocellular carcinoma (HCC) observed in Trials 108 and 110.2,a,c

Table depicting HCC surveillance at Week 240 for VEMLIDY® (tenofovir alafenamide) vs TDF (tenofovir disoproxil fumarate)

HCC surveillance was included as part of the 96-week protocol amendments for Trials 108/110. These trials were not powered to look at any treatment effect on HCC and no results should be drawn based on these observations. This information is not in the VEMLIDY Prescribing Information.1,2

AR=adverse reaction; TDF=tenofovir disoproxil fumarate.
aFrequencies of adverse reactions are based on all treatment-emergent adverse events, regardless of relationship to study drug.1
bGrouped term including abdominal pain upper, abdominal pain, abdominal pain lower, and abdominal tenderness.1
c3 cases of HCC were observed in the open-label TDF➔VEMLIDY group, all of which developed before Week 48 of the open-label phase.2

Use of VEMLIDY in special populations1

Icon of pregnant woman

Pregnancy

  • There is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to VEMLIDY during pregnancy. Healthcare providers are encouraged to register patients by calling the Antiretroviral Pregnancy Registry (APR) at 1-800-258-4263
  • Available data from the APR show no statistically significant difference in the overall risk of birth defects for tenofovir alafenamide (TAF) compared with the background rate for major birth defects of 2.7% in the US reference population of the Metropolitan Atlanta Congenital Defects Program (MACDP). The rate of miscarriage is not reported in the APR. The estimated background rate of miscarriage in clinically recognized pregnancies in the US general population is 15% to 20%
  • Based on prospective reports to the APR of over 660 exposures to TAF-containing regimens during pregnancy resulting in live births (including over 520 exposed in the first trimester and over 130 exposed in the second/third trimester), the prevalence of birth defects in live births was 4.2% (95% CI: 2.6% to 6.3%) and 3.0% (95% CI: 0.8% to 7.5%) following first and second/third trimester exposure, respectively, to TAF-containing regimens. Methodological limitations of the APR include the use of MACDP as the external comparator group. The MACDP population is not disease-specific, evaluates women and infants from a limited geographic area, and does not include outcomes for births that occurred at less than 20 weeks’ gestation
Icon depicting geriatric use

Geriatric use

  • VEMLIDY has been administered to 89 patients aged 65 and over in clinical trials, and no differences in safety or efficacy have been observed between these patients and younger patients
Icon depicting hemodialysis treatment

Patients with end stage renal disease (ESRD)

  • No dosage adjustment is needed for patients with ESRD (eCrCl <15 mL/min) receiving chronic hemodialysis
    • In patients on chronic hemodialysis, on hemodialysis days, administer VEMLIDY after completion of hemodialysis treatment
    • VEMLIDY is not recommended in patients with ESRD who are not receiving chronic hemodialysis
eCrCl=estimated creatinine clearance.

VEMLIDY: No compromise on dose adjustment1,4,5

Go to dosing information

Chronic hepatitis B information for your patients

See educational materials

IMPORTANT SAFETY INFORMATION

BOXED WARNING: POSTTREATMENT SEVERE ACUTE EXACERBATION OF HEPATITIS B

  • Discontinuation of anti-hepatitis B therapy, including VEMLIDY, may result in severe acute exacerbations of hepatitis B. Hepatic function should be monitored closely with both clinical and laboratory follow-up for at least several months in patients who discontinue anti-hepatitis B therapy, including VEMLIDY. If appropriate, resumption of anti-hepatitis B therapy may be warranted.

Warnings and Precautions

  • Risk of Development of HIV-1 Resistance in HBV/HIV-1 Coinfected Patients: Due to this risk, VEMLIDY alone should not be used for the treatment of HIV-1 infection. Safety and efficacy of VEMLIDY have not been established in HBV/HIV-1 coinfected patients. HIV antibody testing should be offered to all HBV-infected patients before initiating therapy with VEMLIDY, and, if positive, an appropriate antiretroviral combination regimen that is recommended for HBV/HIV-1 coinfected patients should be used.
  • New Onset or Worsening Renal Impairment: Postmarketing cases of renal impairment, including acute renal failure, proximal renal tubulopathy (PRT), and Fanconi syndrome have been reported with TAF-containing products. Patients with impaired renal function and/or taking nephrotoxic agents (including NSAIDs) are at increased risk of renal-related adverse reactions. Discontinue VEMLIDY in patients who develop clinically significant decreases in renal function or evidence of Fanconi syndrome. Monitor renal function in all patients – See Dosage and Administration.
  • Lactic Acidosis and Severe Hepatomegaly with Steatosis: Fatal cases have been reported with the use of nucleoside analogs, including tenofovir disoproxil fumarate (TDF). Discontinue VEMLIDY if clinical or laboratory findings suggestive of lactic acidosis or pronounced hepatotoxicity develop, including hepatomegaly and steatosis in the absence of marked transaminase elevations.

Adverse Reactions

Most common adverse reactions (incidence ≥5%; all grades) in clinical studies through week 144 were headache, upper respiratory tract infection, abdominal pain, cough, back pain, arthralgia, fatigue, nausea, diarrhea, dyspepsia, and pyrexia.

Drug Interactions

  • Coadministration of VEMLIDY with drugs that reduce renal function or compete for active tubular secretion may increase concentrations of tenofovir and the risk of adverse reactions.
  • Coadministration of VEMLIDY is not recommended with the following: oxcarbazepine, phenobarbital, phenytoin, rifabutin, rifampin, rifapentine, or St. John’s wort. Such coadministration is expected to decrease the concentration of tenofovir alafenamide, reducing the therapeutic effect of VEMLIDY. Drugs that strongly affect P-glycoprotein (P-gp) and breast cancer resistance protein (BCRP) activity may lead to changes in VEMLIDY absorption.

Consult the full prescribing information for VEMLIDY for more information on potentially significant drug interactions, including clinical comments.

Dosage and Administration

  • Testing Prior to Initiation: HIV infection.
  • Prior to or When Initiating, and During Treatment: On a clinically appropriate schedule, assess serum creatinine, estimated creatinine clearance, urine glucose, and urine protein in all patients. In patients with chronic kidney disease, also assess serum phosphorus.
  • Dosage in Adults: 1 tablet taken once daily with food.
  • Renal Impairment: Not recommended in patients with end stage renal disease (ESRD; eCrCl <15 mL/min) who are not receiving chronic hemodialysis; in patients on chronic hemodialysis, on hemodialysis days, administer VEMLIDY after completion of hemodialysis treatment.
  • Hepatic Impairment: Not recommended in patients with decompensated (Child-Pugh B or C) hepatic impairment.

INDICATION

VEMLIDY is indicated for the treatment of chronic hepatitis B virus (HBV) infection in adults with compensated liver disease.

Please see full Prescribing Information for VEMLIDY, including BOXED WARNING.